BIO Asia–Taiwan 2023 亞洲生技大會
BIO Asia–Taiwan 2023 亞洲生技大會
≡
ENGLISH
中文
ABOUT
About BIO Asia–Taiwan 2023
Organizing Committee
International Committee
Contact Us
Venue
REGISTRATION
Schedule at a Glance
Registration
PROGRAM
2023 Schedule
2023 Conference Overview
2023 Conference Agenda
2023 Company Presentations
2022 Conference Agenda
2022 Regional Collaboration Forum
2022 Focus Symposia & Workshop
PARTNERING
BIO One-on-One Partnering™
2022 Partnering Companies
EXHIBITION
Exhibition Overview
Floor Plan
Exhibitor List
MEDIA
NEWS
Media Coverage
2021/11/4 BIO Asia–Taiwan 2021 Exhibition returns to TaiNEX 2, 4-7 Nov
2021/6/17 BIO Asia–Taiwan 2021 to Go Ahead in ‘All Online’ Format
2021/6/6 BIO Asia–Taiwan 2021 Conference and Exhibition to be held as scheduled
Banners
SPONSORS
Sponsorship Information
2023 Sponsor List
HOTELS & TRAVEL
Hotels
Visa Information
Venue & Transportation
Undiscovered Taipei
EDUCATIONAL
ABOUT
〉
About BIO Asia–Taiwan 2023
Organizing Committee
International Committee
Contact Us
Venue
REGISTRATION
〉
Schedule at a Glance
Registration
PROGRAM
〉
2023 Schedule
2023 Conference Overview
2023 Conference Agenda
2023 Company Presentations
2022 Conference Agenda
2022 Regional Collaboration Forum
2022 Focus Symposia & Workshop
PARTNERING
〉
BIO One-on-One Partnering™
2022 Partnering Companies
EXHIBITION
〉
Exhibition Overview
Floor Plan
Exhibitor List
MEDIA
〉
NEWS
Media Coverage
2021/11/4 BIO Asia–Taiwan 2021 Exhibition returns to TaiNEX 2, 4-7 Nov
2021/6/17 BIO Asia–Taiwan 2021 to Go Ahead in ‘All Online’ Format
2021/6/6 BIO Asia–Taiwan 2021 Conference and Exhibition to be held as scheduled
Banners
SPONSORS
〉
Sponsorship Information
2023 Sponsor List
HOTELS & TRAVEL
〉
Hotels
Visa Information
Venue & Transportation
Undiscovered Taipei
EDUCATIONAL
〉
ENGLISH
中文
PROGRAM
2023 Schedule
2023 Conference Overview
2023 Conference Agenda
2023 Company Presentations
2022 Conference Agenda
2022 Regional Collaboration Forum
2022 Focus Symposia & Workshop
2022 Conference Agenda
BIO Asia–Taiwan 2022
Conference Agenda
Date
July 27-29, 2022
Venue
TaiNEX2, Taipei + Online event platform
Day 1 -
Wednesday, July 27
Day 2 -
Thursday, July 28
Day 3 -
Friday, July 29
09:00 – 10:35
Session 1 (Plenary) – Global Biotech Development
09:00 – 09:05
Welcome
Johnsee Lee, Chairman of BIO Asia–Taiwan 2022
09:05 – 09:15
Opening Remark
Lai Ching-Te, Vice President, Taiwan
09:15 – 09:20
VIP Remarks
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
09:20 – 09:30
Opening Ceremony for Conference
09:30 – 09:45
Keynote Speech- Top iPS Cell Technologies at Affordable Prices
Shinya Yamanaka M.D., Ph.D., Nobel Prize Laureate
Representative Director, CiRA Foundation
09:45 – 10:00
Bioconvergence: Potential Future Impacts to Personalized Medicine
Laura Matz, Chief Science & Technology Officer at Merck KGaA
10:00 – 10:15
The ‘New Normal’: transforming healthcare and implications for Pharma
Graham Lewis, Vice President, Global Pharma Strategy, IQVIA
10:15 – 10:30
Future of Health – How to transform BioPharma for the upcoming LIFEcare system
Thomas Solbach, Partner and Europe Pharma & Life Science Leader, PwC Strategy& (Germany) GmbH
10:40 – 11:40
Session 2 (Plenary) – Global Biotech Development
10:40 – 10:55
A Dynamic Global Supply Chain with Policy Consideration
John A. Murphy, III, Chief Policy Officer Deputy Counsel, Healthcare, Biotechnology Innovation Organization (BIO)
10:55 – 11:10
2022 Health Trends: Appropriate Acceleration in Clinical Development
Ken J. Lee, General Manager and Region Head, Asia Pacific, Syneos Health
11:10 – 11:25
New Horizons for Silicon Nanotechnology in Healthcare
Paru Deshpande, Vice President R&D, imec
11:25 – 11:40
Genomics England: Enabling the Next Chapter of the UK’s Contribution in Genomics
Chris Wigley, Chief Executive Officer, Genomics England
12:20 – 13:50
Session 3 – International Collaboration Strategy
12:20 – 12:25
Opening Remarks
Henry Chen, President, IRPMA; President, Chugai Pharma Taiwan
12:25 – 12:35
Clinical Trial Ecosystem
Mick Stanley, General Manager, GlaxoSmithKline Taiwan
12:35 – 12:45
Collaboration between Pharma and Technology Companies on Digital Health - The Power of Cross-industry Partnering
Jorge Wagner, General Manager & Country President, Novartis Taiwan
12:45 – 12:55
How MNCs Support Taiwan for its Precision Medicine Development?
Cellina Yeh, Country Manager, Pfizer Taiwan
12:55 – 13:40
Panel Discussion
Moderator:
Johnsee Lee, Chairman of BIO Asia–Taiwan 2022
Panelists:
Ramanathan Velayutham, Standing Director, IRPMA; General Manager, Abbvie Taiwan
Jang-Hwa Leu, Director General, Industrial Development Bureau, Ministry of Economic Affair
Donald TF Shang, Director General, Department of Social Insurance, Ministry of Health and Welfares
13:40 – 13:50
Closing Remarks
Ramanathan Velayutham, Standing Director, IRPMA
14:00 – 15:30
Session 4 – Exit Strategies for Early Stage New Drug Companies
14:00 – 14:05
Opening Remarks
Joseph Chou, Chairman and CEO, PwC Taiwan
14:05 – 15:30
Panel Discussion
Moderator:
Timothy K. Lu, Co-founder & CEO, Senti Biosciences
Panelists:
Seth Lieblich, Principal, 8VC
Eckard Weber, Venture Partner, Canaan Partners / Advisory Partner, Domain Associates
Dennis Podlesak, CEO and Managing Partner, Canaan Partners’ Axceliux
Portia Ku, Partner, O'Melveny
George Yeh, President, TLC Biosciences
15:40 – 17:10
Session 5 – New Modalities to Cure
15:40 – 15:45
Opening Remarks
Chung-Hsiun Wu, President, Development Center for Biotechnology
15:45 – 16:00
Delivering on the next mRNA-based breakthroughs
Kathy Fernando, Vice President, Head of mRNA Scientific Strategy, Pfizer
16:00 – 16:15
Regeneration of urethral muscle in Stress Urinary Incontinence using engineered mRNA
Klaas Zuideveld, CEO, Versameb AG
16:15 – 16:30
Innovation insight: An analysis of the evolving landscape of nucleic acid-based therapeutics
Tracy Humphries, mRNA Segment Marketing Leader, Cytiva
16:30 – 16:45
Tailoring Lipid Nanoparticles to Enable RNA Delivery to a Variety of Tissues
Dominik Witzigmann, CEO, Nanovation Therapeutics
16:45 – 17:00
Development of Nucleic Acid Medicine in Relation with CDMO
Tsai-Kun Li, Vice President, Development Center for Biotechnology
17:00 – 17:05
Closing Remarks
Chung-Hsiun Wu, President, Development Center for Biotechnology
09:00 – 10:30
Session 6 - BIO Asia–Taiwan 2022 Opening & Award Ceremony (By Invitation Only)
09:00 – 09:30
Admission
09:30 – 09:35
Introducing Honorable Guests
09:35 – 09:37
Welcome Remarks
Johnsee Lee, Chairman of BIO Asia–Taiwan 2022
09:37 – 09:40
Opening Speech
Tsai Ing-wen, President, Taiwan
09:40 – 09:43
VIP Remarks
Chen Chien-Jen, Former Vice President, Taiwan
09:43 – 09:46
VIP Remarks
Michelle McMurry-Heath, President & CEO, Biotechnology Innovation Organization
09:46 – 10:05
2022 Taiwan BIO Awards Ceremony
10:05 – 10:15
Ribbon-cutting Ceremony
10:15
Adjourn
10:40 – 12:00
Session 7 – Future Pandemic Preparedness
10:40 – 10:45
Opening Remarks
Chung-Hsiun Wu, Chairman, Taiwan Bio Industry Organization
President, Development Center for Biotechnology
10:45 – 11:05
Development of Universal COVID Vaccine
Chi-Huey Wong, Welch and Wolf Prize Laureate; Academician, Academia Sinica; Scripps Family Chair Professor of Chemistry, The Scripps Research Institute
11:00 – 11:15
Stopping the Next Pandemic Before It Starts
Rasmus Bech Hansen, Co-founder and CEO at Airfinity Ltd
11:15 – 11:30
Post COVID-19 Pandemic Health Challenges: How to expedite such a trial for the treatment of COVID Long Haulers
Kazem Kazempour, President and CEO, Amarex Clinical Research
11:30 – 12:00
Panel Discussion: Readiness to Contain Pandemic-the Role of Industry with Public-Private Partnership
Moderator:
Chung-Hsiun Wu, Chairman, Taiwan BIO; President, Development Center for Biotechnology
Panelists:
Kung-Yee Liang, President, National Health Research Institutes
Martin King, Global Head of Public Sector, Airfinity Ltd
Kazem Kazempour, President and CEO, Amarex Clinical Research
12:20 – 13:50
Session 8 – Healthcare Innovation Strategy
12:20 – 12:23
Welcome Remark
Chii-Wann Lin, Vice President and General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
12:30 – 12:30
Opening Remarks
Dan Wang, Regional Head, Johnson & Johnson Innovation, Asia Pacific
12:30 – 12:45
Building a Sustainable BioTech Ecosystem with Taiwan
Chii-Wann Lin, Vice President and General Director, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
12:45 – 13:15
Integrating Global Innovation Networks
Stephen Lee, Director, Early Innovation Partnering, North Asia, Johnson & Johnson Innovation, Asia Pacific
Sharon Chan, Head of Johnson & Johnson Innovation – JLABS, Asia Pacific
Wei Wu, Principal, Venture Investments, Johnson & Johnson Innovation – JJDC
13:15 – 13:50
Panel Discussion: Accelerating Innovation Through External Collaboration
Moderator:
Stephen Lee, Director, Early Innovation Partnering, North Asia, Johnson & Johnson Innovation, Asia Pacific
Panelists:
Andrew Wong, VP Transactions & Early Innovation Partnering, Johnson & Johnson Innovation, Asia Pacific
Ming-Kuei Jang, CEO, Aprinoia (JLABS@Shanghai resident)
Chi-Chun (Jeremy) Lee, Professor, National Tsing Hua University (NTHU)
Hsing-chen Tsai, Principal Investigator, Internal Medicine Department, National Taiwan University Hospital (NTUH)
Kang-Li Wang, Associate Researcher, Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute (ITRI)
14:00 – 15:30
Session 9 –
Winning the Global Competition with Taiwanese DNA
14:00 – 14:03
Opening Remarks
Michael Huang, Managing Partner, Bio Fund
Taiwania Capital Management Corp.
14:03 – 14:18
Why Adoption Strategy is Critical to Digital Health?
Lenny Chen, Executive Consultant, Presentality
14:18 – 14:33
Bridging the Gap between Academia and Commercialization: From the Healthcare Perspective
Yu Chuan Jack Li, Distinguished Professor, Graduate Institute of Biomedical Informatics, Taipei Medical University
14:33 – 14:48
The Common Misconception of ICT in Healthcare
Jerry Chang, President, FaceHeart Corporation
14:48 – 15:27
Panel Discussion: How Do We Survive and Thrive?
Moderator:
Victoria Wang, Principal, Bio Fund
Taiwania Capital Management Corp.
Panelists:
Jim Long, Co-Founder & Chief Executive Officer, AESOP Technology
Tien-Jen Liu, MD, Co-Founder & Chief Operating Officer, AIXMED Inc.
Jerry Chang, President, FaceHeart Corporation
Ed Deng, Co-Founder & Chief Executive Officer, Health2Sync
15:27 – 15:30
Closing Remarks
Michael Huang, Managing Partner, Bio Fund
Taiwania Capital Management Corp.
15:40 – 17:10
Session 10 – AI & Digital Health
15:40 – 15:45
Opening Remarks
Huey-Kang Sytwu, Vice President, National Health Research Institutes
15:45 – 16:00
Managing Trial Planning and Design with Artificial Intelligence
Aparajeeta Priyadarasini, Manager, Solution Consulting, Medidata
16:00 – 16:15
Overview of Decentralized Clinical Trial (DCT)
-Planning & Implementation in APAC
Grace Lin, Director of Clinical Development, Therapeutic Strategy & Innovation, Oncology, Syneos Health
16:15 – 16:30
Investment Trends in Digital Health
Chia-Jui Su, Co-Head of Healthcare & Life Science, KPMG in Taiwan
16:30 – 16:45
Artificial Intelligence Advanced Precision Medicine for Metabolic Diseases
Ting-Fen Tsai, Professor, Department of Life Sciences and Institute of Genome Sciences in National Yang Ming Chiao Tung University
16:45 – 17:00
Data insights: Along the patient journey
Sylvia Wong, Customer Success Manager, Roche Diagnostics
17:00 – 17:10
Closing Remarks
Huey-Kang Sytwu, Vice President, National Health Research Institutes
09:00 – 10:30
Session 11 – Novel Platforms for Biopharma Discovery
09:00 – 09:05
Opening Remarks
Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
09:05 – 09:20
Engineering Gene-Circuit-Enhanced Natural Killer Cell Therapies for Oncology
Timothy K. Lu, Co-founder & CEO, Senti Biosciences; Associate Professor of MIT Biological Engineering and Electrical Engineering and Computer Science
09:20 – 09:40
Preemptive Genetic Profiling for Drug Development and Health Management
Pui-Yan Kwok, Distinguished Research Fellow and Director, Institute of Biomedical Sciences; Academician, Academia Sinica
09:40 – 10:00
1 Cell, 2 Weeks, 3D Culture to Find a Drug:
Single Cell 3D Culture Technology Accelerating Precision Medicine
Ying Chih Chang, Professor, Genomics Research Center, Academia Sinica; Founder, AcroCyte Therapeutics
10:00 – 10:15
Machine Learning Driven Protein Engineering
Tristan Bepler, Group Leader, Simons Machine Learning Center, New York Structural Biology Center; Co-Founder and CEO of OpenProtein.AI
10:15 – 10:30
Conclusion Remarks
Jung-Hsin Lin, Research Fellow/Deputy Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
Closing Remarks
Han-Chung Wu, Director, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taiwan
10:40 – 12:10
Session 12 – Biologics Product Development and Manufacturing
10:40 – 10:42
Opening Remarks
Lee-Cheng Liu, Dr.Sci.Eng., Founder, Chairman and President of EirGenix, Inc.
10:42 – 11:02
Antibody Drug Conjugates (ADCs):
Decades of study, successful product developments and a resurgence of interest
John M. Lambert, PhD, John Lambert Consulting, former Executive VP Emeritus & Distinguished Research Fellow
11:02 – 11:22
Development and Industrialization of Advanced Biomanufacturing Platform to Address Business Needs and Affordability of Biologics
Christopher Hwang, PhD, Executive Vice President, Chief Technology Officer at Transcenta
11:22 – 11:42
New Transformational Technologies for High-Quality and Cost-Effective Viral Vector Production to Enable Gene Therapies Development
David Chang, PhD, CEO, WuXi Advanced Therapies
11:42 – 12:10
Panel Discussion
Moderator: Lee-Cheng Liu, Founder, Chairman and President of EirGenix, Inc.
Panelists:
Christopher Hwang, Executive Vice President, Chief Technology Officer at Transcenta
David Chang, CEO, WuXi Advanced Therapies
Karen Wen, Chief Operating Officer / Chief Strategy Officer, GenomeFrontier Therapeutics,Inc.
Steve Lee, Director of the Board and CEO, Eden Biologics
12:20 – 13:50
Session 13 – Advances in Cell & Gene Therapy
12:20 – 12:25
Opening Remarks
Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
12:25 – 12:40
Reimaging the future of Cancer Care, the Asia Pacific Experience
Joseph Liu, Commercial Head, Cell and Gene Therapy, Asia Pacific Region, Novartis
12:40 – 12:55
Promise Fulfilled? The Next Decade of Cell, Gene, and RNA Therapies
William Xu, Medical Strategy Director, IQVIA
12:55 – 13:10
Planning for Success: Future-proofing the Cell Therapy Process
David Loong, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy, Merck Life Science
13:10 – 13:25
TMU Research Center for Cell Therapy and Regeneration Medicine
Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
13:25 – 13:50
Panel Discussion
Moderator:
Kang-Yun Lee, Dean, Research and Development, Professor, Division of Thoracic Medicine, Taipei Medical University
Panelists:
Hong-Nerng Ho, General Consultant, Chair Professor, College of Medicine, Taipei Medical University and Director, Research Center for Cell Therapy and Regeneration Medicine
Susy Liang, President, Taiwan Hitachi Asia Pacific Co., Ltd.
Joseph Liu, Commercial Head, Cell and Gene Therapy, Asia Pacific Region, Novartis
William Xu, Medical Strategy Director, IQVIA
David Loong, Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy, Merck Life Science
14:00 – 15:30
Session 14 – CDMO Business for Small Molecules
14:00 – 15:30
Panel Discussion
Moderator:
Jo Shen, Venture Partner, Vivo Capital
Panelists:
Edward Hsieh, Vice President, Formosa Laboratories
Bobby Sheng, Group CEO & Chairman, Bora Pharmaceuticals
Roberto Gardellin, Global Health, Serialization & EMG Risk Management Head, Sanofi
Vijay Sabesan, Senior VP, Technical Operations, Kymera Therapeutics
Manuel Sanz, CFO/COO, Oncomatryx Biopharma
15:40 – 18:00
Special Forum – Emerging opportunities when ICT meets BIO
15:40 – 15:45
Opening Remarks
Johnsee Lee, Chairman, Precision Medicine Industry Association of Taiwan
Liang-Gee Chen, President, Taiwan Digital Health Industry Development Association
15:45 – 16:00
Building a Smart Cloud Computing Ecosystem for Healthcare
Barry Lam, Chairman & CEO, Quanta Group
16:00 – 16:15
Introduction to the Digital Patient Solution -Unify
Matthew Bonam, Head of Digital Health, BioPharmaceuticals R&D, AstraZeneca
16:15 – 16:30
Ubiquitous Smart Healthcare in the Digital Era
Chang Yu, Director of Healthcare & Life Science, AWS GCR
16:30 – 16:45
Integration of Biomolecular Sensor Technologies on a Silicon Platform
Pol Van Dorpe, Fellow of the Life Science Technologies Department, imec
16:45 – 18:00
Panel Discussion: Opportunities & Strategy When ICT Meets BIO
Johnsee Lee, Chairman, Precision Medicine Industry Association of Taiwan
Liang-Gee Chen, President, Taiwan Digital Health Industry Development Association
Barry Lam, Chairman & CEO, Quanta Group
Pan-Chyr Yang, Academician, Academia Sinica
Andrew Lin, Chairman, TaiRx, Inc